An ethical framework for the clinical use of Alzheimer’s disease biomarker testing

npj Dementia 2026 Open access

Read full text
Authors: Catherine E. A. Scipion, Michelle M. Mielke, Allyson C. Rosen, Suzanne E. Schindler, Jalayne J. Arias
DOI: 10.1038/s44400-026-00060-4
Cited by: 1
References: 41

Abstract

Abstract This paper proposes a conceptual ethical framework to guide decision-making around blood-based biomarker (BBM) testing for Alzheimer’s disease in primary care, where patients often present with cognitive impairment and multiple chronic conditions. Grounded in current evidence and ethical principles, it addresses clinical benefit, patient values, risk, and justice. Developed by a multidisciplinary team, the framework is illustrated through real-world case scenarios and highlights future research needs to support ethical implementation.

Fields of Study & Subjects

Dementia and Cognitive Impairment Research Alzheimer's disease research and treatments Ethics in Clinical Research

Publication details

Journal / source
npj Dementia
Publisher
Springer Science and Business Media LLC
Volume
2
Issue
1
Publication date
19 February 2026
Language
EN